Literature DB >> 16686730

Telomerase activity in disseminated prostate cancer cells.

Jesco Pfitzenmaier1, William J Ellis, Edward W Arfman, Sarah Hawley, Patrick O McLaughlin, Paul H Lange, Robert L Vessella.   

Abstract

OBJECTIVE: To analyse telomerase activity in disseminated prostate cancer cells isolated from bone marrow aspirates taken from men with localized prostate cancer before radical prostatectomy (RP). PATIENTS AND METHODS: Disseminated epithelial prostate cancer cells were isolated from bone marrow aspirates from 69 men with localized prostate cancer before RP, by magnetic column-chromatography enrichment, followed by isolation of fluorescently labelled epithelial cells by micropipetting. We used pools of 10 non-epithelial bone marrow cells after tumour cell enrichment as control samples. These pure cell pools were tested for the presence of telomerase activity.
RESULTS: In all, 49 of the patient samples contained disseminated prostate cancer cells. Homogeneous pools of 10 cells were obtained from 35 of these; 49% of the 35 specimens showed telomerase activity, whereas all five control samples did not. Telomerase activity in the 35 samples was not significantly associated with Gleason score, preoperative prostate-specific antigen level, tumour stage, or surgical margin status. Follow-up is continuing to assess an association with disease recurrence.
CONCLUSION: This work shows the feasibility of isolating disseminated cancer cells for analysing individual or pooled cells. Compared to tissue staining, where telomerase is detected in 80-90% of samples, we found lower rates of telomerase activity in the disseminated tumour cells (49%). Telomerase-negative cells might provide information about cell dormancy, as telomerase is a marker of cell proliferation in immortal and cancer cells. Telomerase-positive cells might predict early disease recurrence, but a longer follow-up is needed to test this possibility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686730     DOI: 10.1111/j.1464-410X.2006.06194.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

1.  Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy.

Authors:  Nicholas R Perkons; Ryan M Kiefer; Michael C Noji; Mehrdad Pourfathi; Daniel Ackerman; Sarmad Siddiqui; David Tischfield; Enri Profka; Omar Johnson; Stephen Pickup; Anthony Mancuso; Austin Pantel; Michelle R Denburg; Gregory J Nadolski; Stephen J Hunt; Emma E Furth; Stephen Kadlecek; Terence P F Gade
Journal:  Hepatology       Date:  2020-05-16       Impact factor: 17.425

Review 2.  Classic "broken cell" techniques and newer live cell methods for cell cycle assessment.

Authors:  Lindsay Henderson; Dante S Bortone; Curtis Lim; Alexander C Zambon
Journal:  Am J Physiol Cell Physiol       Date:  2013-02-07       Impact factor: 4.249

Review 3.  The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow.

Authors:  Hung-Ming Lam; Robert L Vessella; Colm Morrissey
Journal:  Drug Discov Today Technol       Date:  2014-03

4.  Microscale Mass Spectrometry Analysis of Extracellular Metabolites in Live Multicellular Tumor Spheroids.

Authors:  Mei Sun; Xiang Tian; Zhibo Yang
Journal:  Anal Chem       Date:  2017-08-16       Impact factor: 6.986

5.  New insights into tumor dormancy: Targeting DNA repair pathways.

Authors:  Elizabeth B Evans; Shiaw-Yih Lin
Journal:  World J Clin Oncol       Date:  2015-10-10

Review 6.  Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications.

Authors:  Federico Rossari; Cristina Zucchinetti; Gabriele Buda; Enrico Orciuolo
Journal:  Cell Oncol (Dordr)       Date:  2019-08-07       Impact factor: 6.730

Review 7.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

8.  Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57kip2a).

Authors:  Pinar Atasoy; Erdal Yilmaz; Onder Bozdogan; Sebnem Ayva; Ertan Batislam
Journal:  Int Urol Nephrol       Date:  2008-06-03       Impact factor: 2.370

Review 9.  Preclinical mouse solid tumour models: status quo, challenges and perspectives.

Authors:  Nicolas Gengenbacher; Mahak Singhal; Hellmut G Augustin
Journal:  Nat Rev Cancer       Date:  2017-10-27       Impact factor: 60.716

10.  The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance.

Authors:  Rajamanickam Baskar; Swee Peng Yap; Kevin Lee Min Chua; Koji Itahana
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.